Analysts’ view on the stock has dramatically changed over the past few months. Currently, only 21% of the 29 analysts ...

UnitedHealth restores financial guidance, Sarepta soars after being notified by the FDA the company may lift its voluntary pause on shipments of Elevidys for ambulatory patients with Duchenne muscular ...

Sarepta Therapeutics (Nasdaq: SRPT) has been cleared by the American medicines regulator to resume shipments of its gene ...